Ginkgo Bioworks Holdings Q3 EPS $(0.16) Misses $(0.09) Estimate, Sales $55.43M Beat $48.08M Estimate
Portfolio Pulse from totan@benzinga.com
Ginkgo Bioworks Holdings (NYSE:DNA) reported Q3 losses of $(0.16) per share, missing the analyst consensus estimate of $(0.09) by 77.78%. However, the company's quarterly sales of $55.43 million beat the analyst consensus estimate of $48.08 million by 15.29%. This represents a 60.98% increase in losses and a 16.52% decrease in sales compared to the same period last year.
November 08, 2023 | 10:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ginkgo Bioworks' Q3 earnings per share missed estimates by 77.78%, but sales beat estimates by 15.29%. This could lead to mixed market reactions.
Ginkgo Bioworks' Q3 earnings per share missed estimates significantly, which could negatively impact the stock price. However, the company's sales beat estimates, which could offset some of the negative impact. The net effect on the stock price is uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100